Italian population study of 37996 RA (prevalence 0.54%) pts w/ and 12875 incident cases (incid rate 33.1/100K), there were 1288 deaths/8yrs (MR 21.3/1K), median age=83; SMR 1.28 (1.21 to 1.35), higher <45 yrs (2.15). Leading causes CV (37%), cancer (21%) & infxn (11%) https://t.co/wPx5iqW7Nl

Time to pregnancy (TTP) in 2 RA cohorts: PARA (n 245, 2002-10) vs PreCARA (n 215, 2011-23), latter Rx by T2T. Median TTP was 251d vs 91d (p<0·0001). Preg w/in 1 yrs was 42% v 77%. 61% PreCARA in remission https://t.co/qIHwXvfzMy https://t.co/1huBKiarhH

Target trial emulation: biologics or JAK vs RTX in RA-ILD -- abatacept (n=694), JAKi (156), IL-6i (389), or TNFi (734), PS-matched =# RTX; no significant differences (HR 0.74-1.09 NS) in outcomes of resp hosp, lung transplant & death. But ABA (HR 0.84) & JAKi (HR 0.62) had less https://t.co/2ZVyf8neVH

Advanced Practice Rheum: Rheumatoid & Inflammation Testing In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis. https://t.co/UlBuUhtB01 https://t.co/09OEk1OLs2

NEJM: Polymyalgia Rheumatica Drs. Dejaco and Matteson have published and update and review of polymyalgia rheumatica (PMR) in the NEJM. They lay out the initial approach to diagnosis, initial steroid dosing, management over time and when to use steroid sparing therapy. https://t.co/CGXjcY0J3H

Long-Term Bimekizumab Safety Data Adverse effects from bimekizumab through 2 years or more of treatment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) were about as expected from shorter-term data, results from long-term extension studies indicated. https://t.co/hp2jVSGk8G

Real-world safety of tofacitinib vs biologics in 48,167 #PsA pts Rx w/ TOFA (3,166); TNFi (27K); IL-17Ai (20K); risankizumab (4,381); ustekinumab (4,499). Crude IRs/100 PY were 1.78-2.53 for serious infxn, 0.27–0.61 MI/stroke, 0.17–0.42 VTE, & 0.74–1.06 cancer. TOFA had signif https://t.co/dErlkyY9WC

Advanced Practice Rheum: Evaluation of Rheumatic Complaints In this review, Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice. He emphasizes three key priorities: identifying "red flag" conditions (septic https://t.co/DwyO6FySxE

EULAR 2025 Update for Behçet’s syndrome EULAR has updated its recommendations for the management of Behçet’s syndrome, the last being published in 2018. The current update carries no recommendations from the previous version: seven recommendations have content modifications, https://t.co/Xb6KyqsDXf

Economic analysis of ESR & CRP testing (are they same or different?). Compared to doing either ESR OR CRP, they found the ESR + CRP testing was cost-effective strategy, reducing misdiagnoses, followup costs and overall healthcare costs. https://t.co/UU15bxuPKP https://t.co/7aWwBM8CdY

Rush University MDHAQ surveys done on 1,337 pts (excluding primary FM), identified 30% w/ anxiety, 24% depression, 25% fibromyalgia, & 44% w any 3 of these. In this 44%, HIGHER pain (7 vs 4) and RAPID3 (17 vs 8.2) vs those without FM, anxiety, or depression (p< 0.001). https://t.co/xbOKeZj5cm